Literature DB >> 16166979

Gastric cancer.

Gauri Varadhachary1, Jaffer A Ajani.   

Abstract

Gastric cancer is a very challenging malignancy given that it presents late, has complex pathogenetic mechanisms with multiple carcinogenic processes implicated, and is only moderately sensitive to chemotherapy and radiation. Accurate staging for gastric cancer is possible with the availability of sophisticated imaging studies, endoscopic ultrasound, and laparoscopy. Postoperative chemoradiation is the standard of care in high-risk patients with resected primary disease. Recent encouraging results with the preoperative approach need to be studied further and prospectively compared to postoperative chemoradiation. Chemotherapy has yielded better results than best supportive care for metastatic gastric cancer and also improves quality of life, although all of these studies included a small number of patients. The last decade has seen newer agents used alone or in combination, with promising results. We anticipate that improved trial design, availability of molecular techniques, and continued search for better cytotoxic and targeted agents will help develop better treatments for patients with advanced gastric cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16166979

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  14 in total

1.  Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.

Authors:  Jing-Ting Jiang; Yue-Ping Shen; Chang-Ping Wu; Yi-Bei Zhu; Wen-Xiang Wei; Lu-Jun Chen; Xiao Zheng; Jing Sun; Bin-Feng Lu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

2.  Clinicopathologic features of remnant gastric cancer over time following distal gastrectomy.

Authors:  De-Wei Zhang; Biao Dong; Zhen Li; Dong-Qiu Dai
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

3.  The role of taxanes in the management of gastroesphageal cancer.

Authors:  Paola Jimenez; Aditya Pathak; Alexandria T Phan
Journal:  J Gastrointest Oncol       Date:  2011-12

4.  Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.

Authors:  Yu Gong; Jun Ren; Kun Liu; Li-Ming Tang
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

5.  miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer.

Authors:  Dacheng Wen; Songhe Li; Fujian Ji; Hong Cao; Weidong Jiang; Jiaming Zhu; Xuedong Fang
Journal:  Tumour Biol       Date:  2013-01-09

6.  Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach.

Authors:  Lei Lou; Yuan Wang; Jinfeng Cui; Xia Yan; Liying Xue; Yuehong Li
Journal:  Tumour Biol       Date:  2014-02-02

7.  Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.

Authors:  Qing-Fang Li; Ru-Yong Yao; Ke-wei Liu; Hong-Ying Lv; Tao Jiang; Jun Liang
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

8.  Effects of serum containing Chinese medicine Sanpi Pingwei () formula on proliferation and apoptosis of human SGC-7901 cells.

Authors:  Xiao-Yan Dang; Lei Dong; Hai-Tao Shi; Bai-Cang Zou
Journal:  Chin J Integr Med       Date:  2012-09-21       Impact factor: 1.978

Review 9.  Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction.

Authors:  Markus Menges; Thomas Hoehler
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-04       Impact factor: 4.553

Review 10.  Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward.

Authors:  Markus Menges; Thomas Hoehler
Journal:  Gastrointest Tumors       Date:  2014-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.